Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Purpose
This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Intensity modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. It is not yet know if cetxiumab or chemotherapy, with intensity modulated radiation therapy works best for the treatment of patients with head and neck cancer who are unable to receive cisplatin.
Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Head and Neck Squamous Cell Carcinoma
- Stage III Hypopharyngeal Carcinoma AJCC v8
- Stage III Laryngeal Cancer AJCC v8
- Stage III Lip and Oral Cavity Cancer AJCC v8
- Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IVA Hypopharyngeal Carcinoma AJCC v8
- Stage IVA Laryngeal Cancer AJCC v8
- Stage IVA Lip and Oral Cavity Cancer AJCC v8
- Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IVB Hypopharyngeal Carcinoma AJCC v8
- Stage IVB Laryngeal Cancer AJCC v8
- Stage IVB Lip and Oral Cavity Cancer AJCC v8
- Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Patients must have pathologically confirmed, previously untreated, unresected
squamous cell carcinoma of the larynx, hypopharynx, oropharynx, or oral cavity
- Local evaluation of p16 status is required for all oropharynx patients prior to
registration
- Local evaluation of p16 status is recommended for non-oropharynx patients prior to
registration
- Locoregionally advanced head and neck squamous cell carcinoma (HNSCC) defined as:
- Non-oropharynx and p16-negative oropharynx cancer: American Joint Commission on
Cancer (AJCC) 8th edition stage III-IVB
- Laryngeal, Hypopharyngeal, Oral Cavity, and p16-Negative Oropharyngeal
Primaries:
- AJCC 8th Edition TNM: T3-4b N0 M0 AJCC 8th Edition Stage: III-IVB
- AJCC 8th Edition TNM: T1-4b N1-3 M0 AJCC 8th Edition Stage: III-IVB
- p16-positive oropharynx cancer: AJCC 8th edition stage III and selected stage
I-II based on smoking status in pack-years
- Eligible p16-Positive Oropharyngeal Primaries
- AJCC 8th Edition TNM: T1-2 N1 M0 AJCC 8th Edition Stage: I
Pack-Years: > 10
- AJCC 8th Edition TNM: T1-2 N2 M0 AJCC 8th Edition Stage: II
Pack-Years: any
- AJCC 8th Edition TNM: T3 N0-1 M0 AJCC 8th Edition Stage: II
Pack-Years: > 10
- AJCC 8th Edition TNM: T3 N2 M0 AJCC 8th Edition Stage: II Pack-Years:
any
- AJCC 8th Edition TNM: T1-3 N3 M0 AJCC 8th Edition Stage: III
Pack-Years: any
- AJCC 8th Edition TNM: T4 N0-3 M0 AJCC 8th Edition Stage: III
Pack-Years: any
- Note: Number of pack-years = [Frequency of smoking (number of
cigarettes per day) × duration of cigarette smoking (years)] /
20
- Note: Cigar and pipe tobacco consumption is not included in
calculating the lifetime pack-years. Marijuana consumption is
likewise not considered in this calculation. There is also no
clear scientific evidence regarding the role of chewing
tobacco-containing products in oropharyngeal cancer, although
this is possibly more concerning given the proximity of the oral
cavity and oropharynx. In any case, investigators should not
count use of non-cigarette tobacco products in the pack-years
calculation
- The following are required prior to registration:
- Imaging of the head and neck with a neck CT or MRI (with contrast, unless
contraindicated) or PET/CT which includes diagnostic-quality CT of the neck
(with contrast, unless contraindicated)
- Chest imaging: Chest CT (with contrast, unless contraindicated) or PET/CT
- Age ≥ 18
- Complete the online tool at www.nrgoncology.org prior to registration and record the
(modified) Charleston Comorbidity Index (CCI), Head and Neck Cancer Intergroup
(HNCIG) omega, and G-8 scores on the registration form in Oncology Patient
Enrollment Network (OPEN)
- Patients must have a contraindication to cisplatin as defined in the following
bullet points:
- Absolute or relative contraindication to cisplatin, defined as ONE OR MORE of
the following prior to registration:
- Creatinine clearance (CrCl) < 60 mL/min by the Cockroft-Gault formula
- Pre-existing peripheral (sensory or motor) neuropathy grade ≥ 2 (per
Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0)
- History of hearing loss, defined as either:
- Existing need of a hearing aid OR
- ≥ 25 decibel shift over 2 contiguous frequencies on a pretreatment
hearing test as clinically indicated OR
- age ≥ 70 with Head and Neck Cancer Intergroup (HNCIG) omega score < 0.80 prior
to registration OR
- Age < 70 with ALL of the following conditions prior to registration (see
Appendix II for calculation instructions):
- HNCIG omega score < 0.80
- (Modified) Charlson Comorbidity Index (CCI) ≥ 1
- G-8 score ≤ 14
- Not pregnant and not nursing
- Participants must be able to safely receive the radiation and drug regimens per
current Food and Drug Administration (FDA)-approved package insert(s), treating
investigator's discretion, and institutional guidelines
- No prior systemic therapy for the study cancer; note that prior systemic therapy for
a different cancer is allowable
- No prior radiotherapy to the region of the study cancer that would result in overlap
of radiation therapy fields
- No prior surgery for the study cancer
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Arm 1 (IMRT, cetuximab) |
Patients undergo IMRT 5 days per week for 35 treatments. Starting within 7 days prior to radiation, patients receive a loading dose of cetuximab IV and then concurrently with radiation on day 1 of each cycle. Cycles repeat every 7 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, PET scan on study and blood sample collection throughout the study. Patients may undergo PET scan or MRI during screening. |
|
|
Active Comparator Arm 2 (IMRT, carboplatin, paclitaxel) |
Patients undergo IMRT 5 days per week for 35 treatments. Starting on day 1 of radiation, patients receive concurrent carboplatin IV and paclitaxel on day 1 of each cycle. Cycles repeat every 7 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, PET scan on study and blood sample collection throughout the study. Patients may undergo PET scan or MRI during screening. |
|
Recruiting Locations
Beverly Hills, California 90211
Los Angeles, California 90033
Site Public Contact
323-865-0451
Los Angeles, California 90048
Newark, Delaware 19713
Newark, Delaware 19713
Newark, Delaware 19718
Wilmington, Delaware 19801
Bay Pines, Florida 33744
Bloomington, Illinois 61701
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Chicago, Illinois 60611
Decatur, Illinois 62526
Decatur, Illinois 62526
Eureka, Illinois 61530
Galesburg, Illinois 61401
Glenview, Illinois 60026
Site Public Contact
312-695-1102
Grayslake, Illinois 60030
Site Public Contact
312-695-1102
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Macomb, Illinois 61455
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61615
Peoria, Illinois 61637
Peru, Illinois 61354
Princeton, Illinois 61356
Washington, Illinois 61571
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Kansas City, Kansas 66160
Overland Park, Kansas 66210
Overland Park, Kansas 66211
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Louisville, Kentucky 40245
Cape Girardeau, Missouri 63703
Kansas City, Missouri 64116
Site Public Contact
913-588-3671
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Cincinnati, Ohio 45219
Sylvania, Ohio 43560
Toledo, Ohio 43606
West Chester, Ohio 45069
Chadds Ford, Pennsylvania 19317
Antigo, Wisconsin 54409
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
New Berlin, Wisconsin 53151
Site Public Contact
414-805-0505
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Rhinelander, Wisconsin 54501
Stevens Point, Wisconsin 54481
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
More Details
- Status
- Recruiting
- Sponsor
- NRG Oncology
Study Contact
Detailed Description
PRIMARY OBJECTIVE: I. To determine whether radiation therapy (RT) and concurrent carboplatin and paclitaxel (RT + carboplatin and paclitaxel [CP]) improves progression-free survival (PFS) compared to RT with concurrent cetuximab (RT + cetuximab [Cetux]) in patients with locoregionally advanced head and neck cancer (HNC) who have a contraindication to cisplatin. SECONDARY OBJECTIVES: I. To compare overall survival (OS) between RT+CP versus (vs.) RT + Cetux. II. To compare PFS and OS by study arm within p16-negative and p16-positive subgroups. III. To compare safety and toxicity of RT+CP vs. RT + Cetux. IV. To compare patterns of failure (locoregional and distant) and competing causes of death of RT+CP vs. RT + Cetux. V. To compare changes in diet, eating, and speech behaviors between RT+CP vs. RT + Cetux. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients undergo intensity modulated radiation therapy (IMRT) 5 days per week for 35 treatments. Starting within 7 days prior to radiation, patients receive a loading dose of cetuximab intravenously (IV) and then concurrently with radiation on day 1 of each cycle. Cycles repeat every 7 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan, positron emission tomography (PET) scan on study and blood sample collection throughout the study. Patients may undergo PET scan or magnetic resonance imaging (MRI) during screening. ARM 2: Patients undergo IMRT 5 days per week for 35 treatments. Starting on day 1 of radiation, patients receive concurrent carboplatin IV and paclitaxel on day 1 of each cycle. Cycles repeat every 7 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, PET scan on study and blood sample collection throughout the study. Patients may undergo PET scan or MRI during screening. After completion of study treatment, patients are followed up at 30 days and then 4, 6, 12, 18, 24, 30 and 36 months then annually thereafter.